Home › Funds › Empyrean Capital Partners, LP › ANIP
Empyrean Capital Partners, LP position in ANIP
ANI PHARMACEUTICALS INC COM · Health Care
Empyrean Capital Partners, LP reported holding 23,000,000 shares of ANIP (ANI PHARMACEUTICALS INC COM) in its Q2 2026 13F filing — a position valued at US$29.7M, representing 0.98% of its reported portfolio and ranking #32 among its reported holdings. Empyrean Capital Partners, LP has disclosed ANIP holdings in 4 of the last 4 reported quarters, going back to Q3 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Empyrean Capital Partners, LP's ANIP position evolved
Empyrean Capital Partners, LP first disclosed a stake in ANIP in Q3 2025 at 23,000,000 shares (US$32.3M). Across 4 filings, Empyrean Capital Partners, LP increased the stake 1 time(s), trimmed it 2 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 23,000,000 shares valued at US$29.7M — a reduction of -500,000 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2025 | 23.00M | $32.30M | New |
| Q4 2025 | 21.00M | $26.49M | Reduce |
| Q1 2026 | 23.50M | $29.09M | Add |
| Q2 2026 | 23.00M | $29.75M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ANIP and 13F data
ANIP (ANI PHARMACEUTICALS INC COM) is a Health Care company. 48 other funds we track also report a position in ANIP — the largest reported positions include Soleus Capital Management, L.P. (US$71.8M), TANG CAPITAL MANAGEMENT LLC (US$58.6M), Global Alpha Capital Management Ltd. (US$46.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ANIP
- Soleus Capital Management, L.P. 867.76K sh · $71.83M · Q2 2026
- TANG CAPITAL MANAGEMENT LLC 707.50K sh · $58.57M · Q2 2026
- Global Alpha Capital Management Ltd. 558.00K sh · $46.19M · Q2 2026
- Ranger Investment Management, L.P. 343.15K sh · $28.41M · Q2 2026
- HBK INVESTMENTS L P 20.15M sh · $26.12M · Q2 2026
- Ikarian Capital, LLC 272.08K sh · $22.52M · Q2 2026
- Jones Hill Capital LP 233.81K sh · $19.35M · Q2 2026
- Penn Capital Management Company, LLC 207.36K sh · $17.18M · Q2 2026
- BOUSSARD & GAVAUDAN GESTION SAS 13.00K sh · $17.07M · Q2 2026
- Parkman Healthcare Partners LLC 202.91K sh · $16.80M · Q2 2026
- Boussard & Gavaudan Investment Management LLP 13.35K sh · $16.46M · Q1 2026
- ABSOLUTE INVESTMENT ADVISERS, LLC 11.72M sh · $15.17M · Q2 2026
More on Empyrean Capital Partners, LP
FAQ
How long has Empyrean Capital Partners, LP held ANIP?
Empyrean Capital Partners, LP has disclosed ANIP holdings in 4 of the last 4 reported quarters, going back to Q3 2025.
What is Empyrean Capital Partners, LP's current position in ANIP?
As of Q2 2026, Empyrean Capital Partners, LP holds 23.00M shares of ANIP (ANI PHARMACEUTICALS INC COM), valued at $29.75M, representing 0.98% of its reported portfolio and ranking #32.
Has Empyrean Capital Partners, LP been buying or selling ANIP?
In the latest 13F filing (Q2 2026), Empyrean Capital Partners, LP reduced its position in ANIP.
Which other funds hold ANIP?
Other major institutional holders of ANIP include Soleus Capital Management, L.P., TANG CAPITAL MANAGEMENT LLC, Global Alpha Capital Management Ltd., among 48 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.